Diffusion Pharmaceuticals Inc

Company Profile

Diffusion Pharmaceuticals Inc had its IPO on 2016-01-04 under the ticker symbol DFFN.

The company operates in the Healthcare sector and Biotechnology industry. Diffusion Pharmaceuticals Inc has a staff strength of 13 employees.

Stock update

Shares of Diffusion Pharmaceuticals Inc opened at $3.8 at the start of the last trading session i.e. 2023-06-02.

The stocks traded within a range of $3.74 - $3.81, and closed at $3.78.

This is a -0.92% slip from the previous day's closing price.

A total volume of 3,480 shares were traded at the close of the day’s session.

In the last one week, shares of Diffusion Pharmaceuticals Inc have slipped by -10.12%.

Diffusion Pharmaceuticals Inc's Key Ratios

Diffusion Pharmaceuticals Inc has a market cap of $7.77 million, indicating a price to book ratio of 0.5113 and a price to sales ratio of 0.

In the last 12-months Diffusion Pharmaceuticals Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-15878764. The EBITDA ratio measures Diffusion Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Diffusion Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -27.86% with a return of equity of -64.64%.

In Q1, Diffusion Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Diffusion Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

0

Its diluted EPS in the last 12-months stands at $-7.25 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Diffusion Pharmaceuticals Inc’s profitability.

Diffusion Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 1.6498. Its price to sales ratio in the trailing 12-months stood at 0.

Diffusion Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$18.40 million

Total Liabilities

$2.13 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Diffusion Pharmaceuticals Inc ended 2023 with $18.40 million in total assets and $0 in total liabilities. Its intangible assets were valued at $18.40 million while shareholder equity stood at $16.28 million.

Diffusion Pharmaceuticals Inc ended 2023 with $0 in deferred long-term liabilities, $2.13 million in other current liabilities, 2040.00 in common stock, $-149688923.00 in retained earnings and $0 in goodwill. Its cash balance stood at $14.65 million and cash and short-term investments were $17.64 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Diffusion Pharmaceuticals Inc’s total current assets stands at $18.40 million while long-term investments were $0 and short-term investments were $2.99 million. Its net receivables were $0 compared to accounts payable of $971455.00 and inventory worth $0.

In 2023, Diffusion Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Diffusion Pharmaceuticals Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price

$3.78

52-Week High

$8.74

52-Week Low

$3.55

Analyst Target Price

$24.75

Diffusion Pharmaceuticals Inc stock is currently trading at $3.78 per share. It touched a 52-week high of $8.74 and a 52-week low of $8.74. Analysts tracking the stock have a 12-month average target price of $24.75.

Its 50-day moving average was $4.14 and 200-day moving average was $5.44 The short ratio stood at 1.24 indicating a short percent outstanding of 0%.

Around 24.1% of the company’s stock are held by insiders while 931.8% are held by institutions.